Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019–2023)

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 95f39b45180ecf55-LAX IP: 118.31.43.22 UTC time: 2025-07-14T20:00:29+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4